一项关于克林霉素在正常受试者和慢性肾功能衰竭患者体内药代动力学的研究。
A studyof the pharmacokinetics of clidamycin in normal subjects and patients with chronic renal failure.
作者信息
Eastwood J B, Gower P E
出版信息
Postgrad Med J. 1974 Nov;50(589):710-2. doi: 10.1136/pgmj.50.589.710.
Abstract
A single dose of 150 mg clindamycin was given to nine patients with terminal renal failure being treated by maintenance haemodialysis and the blood levels were measured. Four of these patients were studied during haemodialysis and five between haemodialyses. Clindamycin (150 mg) was also given orally to four normal subjects. The mean serum half-life in the normal subjects was 2·15 hr. For the dialysis patients the mean serum half-life off dialysis was 1·58 hr while that on dialysis was 1·85 hr. There is evidence that clindamycin is excreted normally in chronic renal failure and that blood levels are not affected by haemodialysis. Normal adult doses, 150-300 mg four times a day, can be given safely in patients with chronic renal failure.
摘要
给9名接受维持性血液透析治疗的终末期肾衰竭患者单次静脉注射150mg克林霉素，并测定血药浓度。其中4名患者在血液透析期间接受研究，5名患者在非透析期间接受研究。还对4名正常受试者口服150mg克林霉素。正常受试者的平均血清半衰期为2.15小时。透析患者非透析期间的平均血清半衰期为1.58小时，透析期间为1.85小时。有证据表明，克林霉素在慢性肾衰竭患者中排泄正常，且血药浓度不受血液透析的影响。慢性肾衰竭患者可安全给予正常成人剂量，即每日4次，每次150 - 300mg。
相似文献
1
A studyof the pharmacokinetics of clidamycin in normal subjects and patients with chronic renal failure.一项关于克林霉素在正常受试者和慢性肾功能衰竭患者体内药代动力学的研究。
Postgrad Med J. 1974 Nov;50(589):710-2. doi: 10.1136/pgmj.50.589.710.
2
Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects.维持性血液透析患者和正常受试者单次肌内注射磷酸克林霉素后血清和血浆中克林霉素的浓度。
Eur J Clin Pharmacol. 1978 Dec 18;14(6):435-9. doi: 10.1007/BF00716386.
3
[The pharmacokinetics of clindamycin in abnormal liver and renal function].[克林霉素在肝肾功能异常时的药代动力学]
Dtsch Med Wochenschr. 1972 Jul 14;97(28):1057-9. doi: 10.1055/s-0028-1107497.
4
Altered serum clearance of intravenously administered clindamycin phosphate in patients with uremia.尿毒症患者静脉注射磷酸克林霉素后血清清除率的改变。
J Clin Pharmacol. 1974 Feb-Mar;14(2):140-4. doi: 10.1002/j.1552-4604.1974.tb02304.x.
5
Clinical significance of falsely elevated vancomycin concentrations in end-stage renal disease.终末期肾病中万古霉素浓度假性升高的临床意义。
Ann Pharmacother. 1999 Jan;33(1):116-8. doi: 10.1345/aph.18114.
6
[Pharmacokinetics of trimethoprim and sulfametrol in patients with end stage renal failure and hemodialysis treatment (author's transl)].甲氧苄啶和磺胺甲恶唑在终末期肾衰竭及血液透析治疗患者中的药代动力学（作者译）
Wien Med Wochenschr. 1980 Feb 29;130(4):171-3.
7
Administration of ticarcillin to patients with severe renal failure.替卡西林用于严重肾衰竭患者的给药。
Chemotherapy. 1974;20(6):339-41. doi: 10.1159/000221824.
8
Isoniazid pharmacokinetics in patients in chronic renal failure.慢性肾功能衰竭患者中异烟肼的药代动力学
Clin Nephrol. 1976 Aug;6(2):365-9.
9
[Pharmacokinetics of beta-methyldigoxin in patients with chronic renal failure treated with extracorporeal dialysis].
Pol Arch Med Wewn. 1977 Sep;58(3):213-21.
10
[Pharmacokinetics of ceftazidime in healthy and renal failure subjects].
Presse Med. 1988 Oct 26;17(37):1917-20.
引用本文的文献
1
Plasma concentration of orally administered amoxicillin and clindamycin in patients receiving haemodialysis.口服阿莫西林和克林霉素在血液透析患者中的血浆浓度。
J Antimicrob Chemother. 2023 Mar 2;78(3):724-731. doi: 10.1093/jac/dkad002.
2
Protection from doxorubicin-induced nephrotoxicity by clindamycin: novel antioxidant, anti-inflammatory and anti-apoptotic roles.克林霉素通过抗氧化、抗炎和抗细胞凋亡作用防治多柔比星所致肾毒性。
Naunyn Schmiedebergs Arch Pharmacol. 2020 Apr;393(4):739-748. doi: 10.1007/s00210-019-01782-4. Epub 2019 Dec 18.
3
Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections.克林霉素的药代动力学变异性及利福平对骨与关节感染患者克林霉素浓度的影响。
Infection. 2015 Aug;43(4):473-81. doi: 10.1007/s15010-015-0773-y. Epub 2015 Apr 3.
4
Clinical pharmacokinetics of antibiotics in patients with impaired renal function.肾功能受损患者抗生素的临床药代动力学
Clin Pharmacokinet. 1992 Mar;22(3):169-210. doi: 10.2165/00003088-199222030-00002.
5
Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects.维持性血液透析患者和正常受试者单次肌内注射磷酸克林霉素后血清和血浆中克林霉素的浓度。
Eur J Clin Pharmacol. 1978 Dec 18;14(6):435-9. doi: 10.1007/BF00716386.
本文引用的文献
1
Intermittent haemodialysis: insertion and care of the silastic-teflon cannula.间歇性血液透析：硅橡胶-聚四氟乙烯套管的插入与护理
Br Med J. 1967 Jul 8;3(5557):88-90. doi: 10.1136/bmj.3.5557.88.
2
Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin).克林霉素（7-氯-7-去氧林可霉素）的血液透析特性
Appl Microbiol. 1969 Mar;17(3):446-8. doi: 10.1128/am.17.3.446-448.1969.
3
Maintenance haemodialysis.
Q J Med. 1969 Jan;38(149):49-89.
4
Absorption, excretion and half-life of clinimycin in normal adult males.克林霉素在正常成年男性中的吸收、排泄及半衰期
Am J Med Sci. 1968 Jul;256(1):25-37. doi: 10.1097/00000441-196807000-00004.
5
Clinical uses and control of rifampicin and clindamycin.利福平与克林霉素的临床应用及控制
J Clin Pathol. 1971 Jul;24(5):410-8. doi: 10.1136/jcp.24.5.410.
6
Microbiological and pharmacological behavior of 7-chlorolincomycin.7-氯林可霉素的微生物学和药理学行为
Appl Microbiol. 1969 May;17(5):653-7. doi: 10.1128/am.17.5.653-657.1969.
7
Clinical and bacteriological studies with clindamycin.克林霉素的临床与细菌学研究。
Br Med J. 1970 Jun 20;2(5711):703-4. doi: 10.1136/bmj.2.5711.703.
8
Septicaemia and pulmonary embolism complicating use of arteriovenous fistula in maintenance haemodialysis.败血症和肺栓塞并发于维持性血液透析中动静脉内瘘的使用。
Lancet. 1970 Aug 8;2(7667):288-90. doi: 10.1016/s0140-6736(70)91331-0.
Zotero 插件